Clinical Presentation and Therapeutic Management of V Children: A Retrospective Analysis

Thrombosis Journal

16, 1-9

DOI: 10.1186/s12959-018-0182-4

Citation Report

#	Article	IF	Citations
1	Rivaroxaban Versus Standard Anticoagulation for Acute Venous Thromboembolism in Childhood. Design of the EINSTEIN-Jr Phase III Study. Thrombosis Journal, 2018, 16, 1-11.	2.9	39
2	Bodyweight-Adjusted Rivaroxaban for Children With Venous Thromboembolism (EINSTEIN-Jr): Results From Three Multicentre, Single-Arm, Phase 2 Studies. Lancet Haematology,the, 2019, 6, e500-e509.	14.9	75
3	Insights Into Neonatal Thrombosis. Thrombosis Research, 2019, 181, S33-S36.	2.9	47
4	Rivaroxaban Compared With Standard Anticoagulants for the Treatment of Acute Venous Thromboembolism in Children: A Randomised, Controlled, Phase 3 Trial. Lancet Haematology,the, 2020, 7, e18-e27.	14.9	307
5	Safety and Efficacy of Anticoagulant Therapy in Pediatric Catheter-Related Venous Thrombosis (EINSTEIN-Jr CVC-VTE). Blood Advances, 2020, 4, 4632-4639.	6.3	51
6	Concordance of Identified Cases of Pediatric HA-VTE With American College of Physicians and Cincinnati Children's Hospital HA-VTE Prophylaxis Guidelines Over a 10-Year Period. Global Pediatric Health, 2020, 7, 2333794X20960279.	1.2	2
7	Rivaroxaban for the Treatment of Venous Thromboembolism in Pediatric Patients. Expert Review of Cardiovascular Therapy, 2020, 18, 733-741.	2.7	17
8	Rivaroxaban for Treatment of Pediatric Venous Thromboembolism. An Einstein-Jr Phase 3 Dose-Exposure-Response Evaluation. Journal of Thrombosis and Haemostasis, 2020, 18, 1672-1685.	5.0	87
9	New Insights Into Neonatal Hemostasis. Thrombosis Update, 2022, 7, 100103.	1.6	3
10	Effects of Dietary Supplementation With Glycerol Monolaurate (GML) or the Combination of GML and Tributyrin on Growth Performance and Rumen Microbiome of Weaned Lambs. Animals, 2022, 12, 1309.	3.2	12
11	50 Years of Pediatric Hemostasis: Knowledge, Diagnosis, and Treatment. Seminars in Thrombosis and Hemostasis, 2023, 49, 217-224.	4.1	17
12	Venous Thromboembolism in Children: The Rivaroxaban Experience. Seminars in Thrombosis and Hemostasis, 2024, 50, 866-872.	4.1	11
13	Retrospective Study Evaluating Safety, Clinical Effect, and Dosing of Dalteparin for the Treatment of Venous Thromboembolism in Term Neonates. Pediatric Blood and Cancer, 2024, 71, e31215.	1.7	1
14	Extended-Phase Anticoagulant Treatment of Acute Venous Thromboembolism in Children: A Cohort Study From the EINSTEIN-Jr Phase 3 Trial. Lancet Haematology,the, 2025, 12, e357-e364.	14.9	9
15	American Society of Hematology/International Society on Thrombosis and Haemostasis 2024 Updated Guidelines for Treatment of Venous Thromboembolism in Pediatric Patients. Blood Advances, 2025, 9, 2587-2636.	6.3	93
16	Pediatric Thrombosis: Risk Factors, Diagnosis, and Prevention Strategies. Medicine (United States), 2025, 104, e43370.	2.1	9
17	Being Overweight: Impact on Disease Conditions. , 2025, .		0
18	Neonatal Thromboembolic Disease: Clinical Spectrum and Emerging Evidence for Diagnostic and Therapeutic Strategies Addressing Unmet Needs. Journal of Clinical Medicine, 2026, 15, 6221.	3.8	2